Pieris Pharmaceuticals, Inc. PIRS
Day range unavailable
52-week range unavailable
- Market cap
- 17.96M
- Revenue (ttm)
- 20.87M
- Profit margin
- -114.12%
- Shares out
- 1.32M
- Forward P/E
- -68.00
- Beta
- 0.66
- Earnings date
- Nov 13, 2024
Key statistics
- Enterprise value
- 1.33M
- PEG ratio
- 0.00
- Price / sales
- 0.86
- Price / book
- 0.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -25.49M
- Total cash
- 19.73M
- Total debt
- 0
- Return on equity
- -80.46%
- Short % of float
- 2.12%
- 50-day average
- 16.46
- 200-day average
- 14.03
Next earnings
Nov 13, 2024
Expected Nov 13, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 29, 2024 | Dec 1, 2023 | -9.60 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -8.80 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -12.80 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 13, 2020 | Baird | up | Neutral | Outperform |
| Jul 30, 2019 | Baird | down | Outperform | Neutral |
| May 14, 2019 | Baird | init | — | Outperform |
| May 4, 2018 | Cowen & Co. | init | — | Outperform |
| Mar 19, 2018 | Evercore ISI Group | init | — | Outperform |
| Mar 19, 2018 | Jefferies | init | — | Buy |
About Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- pieris.com
News
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS 
Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference 
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations 
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders 
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRS 
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders 
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders 
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS 
Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders 
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Your note
Sign in to keep a note on PIRS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| KIRITSY CHRISTOPHER P | Director | Purchase | May 24, 2023 | 20,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 19.51% | 257,626 | 3.50M | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 10.96% | 144,641 | 1.97M | Sep 29, 2024 |
| BML Capital Management, LLC | 3.19% | 42,130 | 572.97K | Sep 29, 2024 |
| Lynx1 Capital Management Lp | 2.84% | 37,436 | 509.13K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 2.44% | 32,171 | 437.52K | Sep 29, 2024 |
| CM Management, LLC | 1.70% | 22,500 | 306.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.84% | 11,069 | 150.54K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.54% | 7,161 | 97.39K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 1,882 | 25.59K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 1,815 | 24.68K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 282 | 3.83K | Oct 30, 2024 |